Lima-Júnior Roberto C P, Oliveira Francisco A, Gurgel Luilma A, Cavalcante Italo J, Santos Kelcyana A, Campos Deive A, Vale Cinthia A, Silva Regilane M, Chaves Mariana H, Rao Vietla S N, Santos Flávia A
Department of Physiology and Pharmacology, Federal University of Ceara, Fortaleza, CE, Brazil.
Planta Med. 2006 Jan;72(1):34-9. doi: 10.1055/s-2005-873150.
In the search for novel natural compounds effective against visceral nociception, the triterpenoid mixture alpha- and beta-amyrin, isolated from Protium heptaphyllum resin, was assessed in two established mouse models of visceral nociception. Mice were pretreated orally with alpha- and beta-amyrin (3, 10, 30, and 100 mg/kg) or vehicle, and the pain-related behavioral responses to intraperitoneal cyclophosphamide or to intracolonic mustard oil were analyzed. The triterpenoid mixture showed a dose-related significant antinociception against the cyclophosphamide-induced bladder pain, and at 100 mg/kg, the nociceptive behavioral expression was almost completely suppressed. Intracolonic mustard oil-induced nociceptive behaviors were maximally inhibited by 10 mg/kg alpha- and beta-amyrin mixture in a naloxone-reversible manner. While pretreatment with ruthenium red (3 mg/kg, s. c.), a non-specific transient receptor potential cation channel V1 (TRPV1) antagonist, also caused significant inhibition, the alpha (2)-adrenoceptor antagonist, yohimbine (2 mg/kg, s. c.), showed no significant effect. The triterpene mixture (10 mg/kg, p. o.) neither altered significantly the pentobarbital sleeping time, nor impaired the ambulation or motor coordination in open-field and rotarod tests, respectively, indicating the absence of sedative or motor abnormalities that could account for its antinociception. These results indicate that the antinociceptive potential of alpha- and beta-amyrin possibly involves the opioid and vanilloid (TRPV1) receptor mechanisms and further suggests that it could be useful to treat visceral pain of intestinal and pelvic origins.
在寻找对内脏痛觉有效的新型天然化合物的过程中,从七叶普罗梯木树脂中分离得到的三萜类混合物α-和β-香树脂醇,在两种已建立的内脏痛觉小鼠模型中进行了评估。小鼠口服给予α-和β-香树脂醇(3、10、30和100mg/kg)或赋形剂进行预处理,然后分析对腹腔注射环磷酰胺或结肠内注射芥子油的疼痛相关行为反应。该三萜类混合物对环磷酰胺诱导的膀胱疼痛表现出剂量相关的显著镇痛作用,在100mg/kg时,伤害性行为表达几乎完全被抑制。结肠内注射芥子油诱导的伤害性行为在10mg/kg的α-和β-香树脂醇混合物作用下被最大程度抑制,且这种抑制作用可被纳洛酮逆转。虽然用非特异性瞬时受体电位阳离子通道V1(TRPV1)拮抗剂钌红(3mg/kg,皮下注射)预处理也会引起显著抑制,但α2-肾上腺素能受体拮抗剂育亨宾(2mg/kg,皮下注射)则无显著作用。该三萜类混合物(10mg/kg,口服)既未显著改变戊巴比妥睡眠时间,也未分别在旷场试验和转棒试验中损害行走或运动协调性,表明不存在可解释其镇痛作用的镇静或运动异常。这些结果表明,α-和β-香树脂醇的镇痛潜力可能涉及阿片类和香草酸类(TRPV1)受体机制,并进一步表明其可能对治疗肠道和盆腔来源的内脏疼痛有用。